BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET Study
Thomas Kaley(Roswell Park Comprehensive Cancer Center), David M. Hyman(Cornell University), Ian Chau(Universitat Autònoma de Barcelona), Jordi Rodón(Universitat Autònoma de Barcelona), Franck Bielle(Centre National de la Recherche Scientifique), Jean‐Yves Blay(Centre Léon Bérard), Florence Joly(Inserm), Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Igor Puzanov(Vanderbilt University Medical Center), Noopur Raje(Dana-Farber Cancer Institute), Ralf‐Dieter Hofheinz(Goethe University Frankfurt), Martina Makrutzki(Roche (Switzerland)), Bethany Pitcher(Roche (Switzerland)), Mehdi Touat(Centre National de la Recherche Scientifique), Antoine Hollebecque(Institut Gustave Roussy), Vicki L. Keedy(Vanderbilt University Medical Center), A. Craig Lockhart(Roswell Park Comprehensive Cancer Center), Jürgen Wolf(Memorial Sloan Kettering Cancer Center), José Baselga(Roche (Switzerland)), Todd Riehl, Lisa M. DeAngelis(Memorial Sloan Kettering Cancer Center)
Cited by 330
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k